What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors?

Journal of Clinical Psychiatry

Volumn 66, Issue 7, 2005, Pages 859-863

  Demyttenaere, Koen ^a   Albert, Adelin ^b   Mesters, Patrick ^c   Dewé, Walthère ^c   De Bruyckere, Katrien ^d   Sangeleer, Michèle ^d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b University Hospital   (Belgium)

^c European Development Center   (Belgium)

^d Eli Lilly Benelux   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; AUTONOMIC DYSFUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; GYNECOLOGIC DISEASE; HABITUATION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MULTICENTER STUDY; NEUROLOGIC DISEASE; OUTPATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECURRENT DISEASE; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN DISEASE;

EID: 22744445310     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0708     Document Type: Article

References (22)

1. Demyttenaere K. Compliance during treatment with antidepressants. J Affect Disord 1997;43:27-39
2. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002;105:164-172
3. Bull S, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants. JAMA 2002;288:1403-1409
4. Lin EHB, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy: influence of patient-physician communication. Med Care 1995;33:67-74
5. Demyttenaere K, Enzlin P, Dewe W, et al. Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. J Clin Psychiatry 2001;62(suppl 22):30-33
6. Kobak KA, Taylor L, Katzelnick DJ, et al. Antidepressant medication management and Health Plan Employer Data Information Set (HEDIS) criteria: reasons for nonadherence. J Clin Psychiatry 2002;63:727-732
7. Maddox JC, Levi M, Thompson C. The compliance with antidepressants in general practice. J Psychopharmacol 1994;8:48-53
8. Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. BMJ 1997;170:120-127
9. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000;58:19-36
10. MacGillivray S, Arroll B, Hatcher S, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 2003;326:1014-1019
11. Trindade E, Menon D, Topfer LA, et al. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998;159:1245-1252
12. Wade A, Lemming OM, Hedegaard KB. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002;17:95-102
13. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331-336
14. Zajecka J, Amsterdam JD, Quitkin FM, et al. Changes in adverse events reported by patients during 6 months of fluoxetine therapy. J Clin Psychiatry 1999;60:389-394
15. Bull SA, Hunkeler EM, Lee JY, et al. Discontinuing or switching selective serotonin reuptake inhibitors. Ann Pharmacother 2002;36:578-584
16. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
17. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;76(suppl 334):1-100
18. Masand PS, Gupta S. Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiatry 1999;7:69-84
19. Linden RD, Wilcox CS, Cavanaugh E, et al. Are selective serotonin reuptake inhibitors well tolerated in somatizing depressives? Psychopharmacol Bull 1994;30:151-156
20. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002;36: 106-132
21. Hildebrandt MG, Steyerberg EW, Stage KB, et al. Are gender differences important for the clinical effects of antidepressants? Am J Psychiatry 2003;160:1643-1650
22. Yonkers KA, Brawman-Mintzer O. The pharmacologic treatment of depression: is gender a critical factor? J Clin Psychiatry 2002;63:610-615